| Literature DB >> 35126331 |
Wanyue Dan1,2, Lihua Peng1, Bin Yan1, Zhengpeng Li1, Fei Pan1.
Abstract
Esophageal adenocarcinoma (EAC) is one of the main subtypes of esophageal cancer. The incidence rate of EAC increased progressively while the 5-year relative survival rates were poor in the past two decades. The mechanism of EAC has been studied extensively in relation to genetic factors, but less so with respect to human microbiota. Currently, researches about the relationship between EAC and the human microbiota is a newly emerging field of study. Herein, we present the current state of knowledge linking human microbiota to esophageal adenocarcinoma and its precursor lesion-gastroesophageal reflux disease and Barrett's esophagus. There are specific human bacterial alternations in the process of esophageal carcinogenesis. And bacterial dysbiosis plays an important role in the process of esophageal carcinogenesis via inflammation, microbial metabolism and genotoxicity. Based on the human microbiota alternation in the EAC cascade, it provides potential microbiome-based clinical application. This review is focused on novel targets in prevention, diagnosis, prognosis, and therapy for esophageal adenocarcinoma.Entities:
Keywords: Barrett’s esophagus; esophageal adenocarcinoma; gastroesophageal reflux disease; microbial therapy; microbiota
Year: 2022 PMID: 35126331 PMCID: PMC8815000 DOI: 10.3389/fmicb.2021.791274
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
FIGURE 1The predominant phyla of esophageal microbiota and oral microbiota. The top six most abundant phyla of esophageal microbiota consisted of Firmicutes (69.60%), Bacteroides (20.20%), Actinobacteria (4.30%), Proteobacteria (2.20%), Fusobacteria (2.20%), TM7 (1.40%); And the top six most abundant phyla of oral microbiota consisted of Proteobacteria (35.34%), Bacteroides (32.20%), Firmicutes (14.48%), Actinobacteria (9.26%), Fusobacteria (3.76%), TM7 (3.25%).
FIGURE 2The process of esophageal carcinogenesis and associated human microbiota. This figure describes specific human bacterial alternations in the normal esophagus, esophageal adenocarcinoma and its precursor lesion—gastroesophageal reflux disease and Barrett’s esophagus.
Human microbiota studies for esophageal adenocarcinoma.
| Study | Population(s) | Study sample size | Study period | Study platform | Sample type | Main findings | Tool type |
|
| Rome | BE ( | 2020 | 16S rRNA | Esophageal mucosa | Diagnosis | |
|
| Australia | RE ( | 2020 | 16S rRNA | Esophageal mucosa | Compared with CTRL, there was a reduction of | Diagnosis |
|
| America | EAC ( | 2017 | 16S rRNA | Mouthwash samples | The abundances of species | Diagnosis |
|
| United States | LGD ( | 2019 | 16S rRNA | Saliva samples | There was a shift toward | Diagnosis |
|
| China | EC ( | 2020 | 16S rDNA | Saliva samples | Diagnosis | |
|
| United Kingdom | IM ( | 2020 | 16S rDNA | Esophageal mucosa | The abundance of the phylum | Diagnosis |
|
| Australia | EoE ( | 2018 | 16S rRNA; 18S rRNA; shotgun sequencing | Esophageal mucosa; esophageal brushings | An enrichment of Gram-negative bacteria associated with the oral cavity and microbial lactic acid production in the EAC cascade | Diagnosis |
|
| United Kingdom | ND ( | 2017 | 16S rRNA | Esophageal mucosa; esophageal brushes; Cytosponge samples | Diagnosis | |
|
| Japan | EC ( | 2020 | PCR | Subgingival dental plaque; saliva samples | The prevalence of | Diagnosis |
|
| Australia | BE ( | 2013 | PCR; immunohistochemistry; | Esophageal mucosa; tumor specimens | High activity of | Prognosis |
|
| Japan | EC ( | 2016 | PCR | Tumor specimens; tumor adjacent normal specimens | Prognosis |
BEM, esophageal metaplastic samples; BE, Barrett’s esophagus; IM, intestinal metaplasia; LGD, low-grade dysplasia; HGD, high-grade dysplasia; BD, Barrett’s dysplasia; EC, esophageal cancer; EAC, esophageal adenocarcinoma; CTRL, healthy control samples; PCR, polymerase chain reaction.
FIGURE 3The molecular mechanisms of microbe-mediated in EAC carcinogenesis. On the basis of the known contribution of human microbiota in esophageal carcinogenesis, the main mechanisms included inflammation, metabolism, and genotoxicity. Alteration of human microbiota in EAC showed a shift toward Gram-negative bacteria. Some specific pathogens, such as Campylobacter concisus, Helicobacter pylori, and Escherichia coli, involved in the process of inflammation and EAC cascade by regulating the expressions of toll-like receptors (TLRs) and pro-inflammatory mediators such as TNF-α, IL-18, COX-2, prostaglandins. And the components of Gram-negative bacteria activated the NLRP3 inflammasome and NF-κB pathway. Besides, detrimental metabolites, such as hydrogen sulfide, products of protein fermentation and bile acid metabolism, could play an important role in the initiation and progression of EAC. Some Gram-negative bacteria produced the cytolethal distending toxin (CDT), which could induce DNA damage and trigger EAC carcinogenesis. LPS, lipopolysaccharides; NF-κB, nuclear factor kappa B; TLRs, toll-like receptors; CDT, cytolethal distending toxin; TNF-α, tumor necrosis factor-α; IL, interleukin; COX, cyclooxygenase; PG, prostaglandin; p53, tumor protein 53; NLRP3, nucleotide-binding domain and leucine-rich repeat-containing protein 3.
FIGURE 4The novel microbiota-related targets in screening, diagnosis, prognosis, and therapy for esophageal adenocarcinoma.